PS
BMRN icon

Planning Strategies’s BioMarin Pharmaceuticals BMRN Stock Holding History

Planning Strategies’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$401 Buy
+7
New +$383 ﹤0.01% 896

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Planning Strategies's BMRN Position: Q2 2026 in Review

Planning Strategies opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 7 shares worth $401. The stake represents ﹤0.01% of the portfolio and ranks #896 among its holdings.

526 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Planning Strategies held 7 shares of BioMarin Pharmaceuticals worth $401 as of Q2 2026.
  • BioMarin Pharmaceuticals was a new Planning Strategies position in Q2 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Planning Strategies's portfolio in Q2 2026, its #896 holding.
  • 526 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Planning Strategies's 13F filing for Q2 2026, filed 27 Jul 2026.